ASLAN PHARMACEU/ADR (NASDAQ:ASLN)’s share price was up 18.9% on Thursday . The company traded as high as $0.44 and last traded at $0.44, approximately 135,354 shares were traded during mid-day trading. An increase of 458% from the average daily volume of 24,273 shares. The stock had previously closed at $0.37.
A number of research analysts recently weighed in on ASLN shares. Piper Jaffray Companies lowered shares of ASLAN PHARMACEU/ADR from an “overweight” rating to a “neutral” rating in a research note on Monday. BTIG Research lowered shares of ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a research note on Monday. ValuEngine raised shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 price target on the stock in a research note on Monday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price target (down from $9.00) on shares of ASLAN PHARMACEU/ADR in a research note on Thursday. They noted that the move was a valuation call. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $3.67.
The stock has a market capitalization of $21.34 million, a PE ratio of -0.31 and a beta of 2.40. The stock’s 50 day moving average is $1.64 and its two-hundred day moving average is $2.66. The company has a debt-to-equity ratio of 1.12, a quick ratio of 3.80 and a current ratio of 1.88.
An institutional investor recently raised its position in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC grew its holdings in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,100 shares of the company’s stock after purchasing an additional 6,993 shares during the quarter. FNY Investment Advisers LLC owned about 0.06% of ASLAN PHARMACEU/ADR worth $33,000 as of its most recent SEC filing. 7.18% of the stock is owned by institutional investors.
ASLAN PHARMACEU/ADR Company Profile (NASDAQ:ASLN)
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Recommended Story: Quiet Period Expirations Explained
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.